http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 11 Mar 2026 06:09:23 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Opus+Genetics+%28IRD%29/26142221.html <p>H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $8.00 price target on Opus Genetics (NASDAQ: IRD).</p><p>The analyst commented: "The company continues advancement across its inherited retinal disease (IRD) platform demonstrating positive initial datasets: (i) OPGx-LCA5 for treating LCA5-related mutations; and (ii) OPGx-BEST1 for treating BEST1-related retinal degeneration. Moreover, the company maintains development for preclinical IRD gene therapies targeting RHO, CNGB1, RDH12-LCA, and NMNAT1, which we presently view as upside. We highlight the preclinical pipeline builds on additional clinical development plans for OPGx-MERTK for MERTK-related retinitis pigmentosa (RP), a disease which otherwise leads to progressive vision loss and subsequent http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Opus+Genetics+%28IRD%29/26142221.html Wed, 11 Mar 2026 06:09:23 -0400 IRD http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Opus+Genetics%2C+Inc.+++++++For%3A+Mar+10/26135269.html si-local-file:///var/storage/secattach/20260310/26135269.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Opus+Genetics%2C+Inc.+++++++For%3A+Mar+10/26135269.html Tue, 10 Mar 2026 07:17:00 -0400 IRD O.01227350 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Opus+Genetics%2C+Inc.+++++++For%3A+Mar+10/26135269.html si-local-file:///var/storage/secattach/20260310/26135269.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Opus+Genetics%2C+Inc.+++++++For%3A+Mar+10/26135269.html Tue, 10 Mar 2026 07:17:00 -0400 IRD O.01227350 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html <p align="center">- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 -</p> <p align="center">- Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program provides opportunity for Opus’ deep pipeline in rare inherited retinal diseases -<br/><br/>- FDA Prescription Drug User Fee Act (PDUFA) date in October 2026 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia -<br/><br/>- Funding from prominent healthcare investors expected to extend cash runway into 2028 -</p> <p>RESEARCH TRIANGLE PARK, N.C., March 10, http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Announces+Financial+Results+for+Full+Year+2025+and+Provides+Corporate+Update/26135127.html Tue, 10 Mar 2026 07:00:00 -0400 A.06822034 A.31913558 A.50216362 A.60012014 A.60012014 IRD O.01227350 O.19986975 O.20026344 O.20032830 O.21247872 O.52736955